2018
DOI: 10.1158/1538-7445.am2018-1630
|View full text |Cite
|
Sign up to set email alerts
|

Abstract 1630: FLT3 chimeric antigen receptor T cell therapy induces B to T cell lineage switch in infant acute lymphoblastic leukemia

Abstract: Though childhood acute lymphoblastic leukemia (ALL) is highly treatable, there remain subsets of pediatric ALL with very poor prognoses. Infant ALL, found in children under the age of 1, is difficult to treat due to the scarcity of cases impeding the ability of even the largest pediatric oncology centers from gaining experience in treating the disease, the more aggressive initial clinical presentation, as well as the inability for these young patients to tolerate toxicities associated with chemotherapeutic reg… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…In both the preclinical and the clinical setting, an analogous phenomenon with emergence of myeloid subtypes following CD19-directed immunotherapy has now been described in ALL with or without KMT2A rearrangement 16,17,110,125 . Similarly, targeting of FLT3 with CAR T cells in preclinical ALL models was found to induce a reversible B cell to T cell lineage switch (while effectively avoiding transformation to FLT3 + myeloid lineage leukaemias) 130 . Whether this resistance mechanism is active in non-leukaemic malignancies remains to be determined.…”
Section: Antigen Loss or Modulation As A Mechanism Of Immune Escapementioning
confidence: 97%
“…In both the preclinical and the clinical setting, an analogous phenomenon with emergence of myeloid subtypes following CD19-directed immunotherapy has now been described in ALL with or without KMT2A rearrangement 16,17,110,125 . Similarly, targeting of FLT3 with CAR T cells in preclinical ALL models was found to induce a reversible B cell to T cell lineage switch (while effectively avoiding transformation to FLT3 + myeloid lineage leukaemias) 130 . Whether this resistance mechanism is active in non-leukaemic malignancies remains to be determined.…”
Section: Antigen Loss or Modulation As A Mechanism Of Immune Escapementioning
confidence: 97%